ALLIANCES AND COLLABORATIONS (Tables)

12 Months Ended

Dec. 31, 2012

Sanofi [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Year Ended December 31,
Dollars in Millions		2012			2011		2010
Territory covering the Americas and Australia:
	Net sales	$	2,766	$	7,761	$	7,464
	Royalty expense		530		1,583		1,527
	Noncontrolling interest – pre-tax		844		2,323		2,074
	Distributions to Sanofi		742		2,335		2,093
Territory covering Europe and Asia:
	Equity in net income of affiliates		201		298		325
	Distributions to BMS		229		283		313
Other:
	Net sales in Europe comarketing countries and other		284		279		378
	Amortization (income)/expense – irbesartan license fee		(29)		(31)		(31)
	Supply activities and development and opt-out royalty (income)/expense		(142)		23		(3)
				December 31,
Dollars in Millions					2012		2011
Investment in affiliates – territory covering Europe and Asia				$	9	$	37
Deferred income – irbesartan license fee					-		29
Noncontrolling interest					(30)		(131)

Sanofi [Member] | Territory Covering Europe and Asia [Member]

Alliances and Collaborations Statement [Line Items]

Equity Method Investments Disclosure [Text Block]

	Year Ended December 31,
Dollars in Millions	2012		2011		2010
Net sales	$	1,077	$	1,469	$	1,879
Cost of products sold		624		811		1,047
Gross profit		453		658		832
Marketing, selling and administrative		47		75		129
Advertising and product promotion		8		15		29
Research and development		2		5		16
Other (income)/expense		2		1		(1)
Net income	$	394	$	562	$	659
Current assets	$	417	$	584	$	751
Current liabilities		417		584		751

Otsuka [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Year Ended December 31,
Dollars in Millions		2012		2011		2010
Abilify*	net sales, including amortization of extension payment	$	2,827	$	2,758	$	2,565
Oncology Products collaboration fee expense			138		134		128
Royalty expense			78		72		62
Reimbursement of operating expenses to/(from) Otsuka			(49)		(47)		(101)
Amortization (income)/expense – extension payment			66		66		66
Amortization (income)/expense – upfront, milestone and other licensing payments			5		6		6
				December 31,
Dollars in Millions				2012		2011
Other assets – extension payment				$	153	$	219
Other intangible assets – upfront, milestone and other licensing payments					-		5

Schedule Of Percentage Of Net Sales Recognized From Collaboration [Text Block]

	Share as a % of U.S. Net
	Sales
$0 to $2.7 billion	50%
$2.7 billion to $3.2 billion	20%
$3.2 billion to $3.7 billion	7%
$3.7 billion to $4.0 billion	2%
$4.0 billion to $4.2 billion	1%
In excess of $4.2 billion	20%

Schedule Of Percentage Of Net Sales Payable As Collaboration Fee [Text Block]

	% of Net Sales
	2010 - 2012	2013 - 2020
$0 to $400 million	30%	65%
$400 million to $600 million	5%	12%
$600 million to $800 million	3%	3%
$800 million to $1.0 billion	2%	2%
In excess of $1.0 billion	1%	1%

Lilly [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

	Year Ended December 31,
Dollars in Millions	2012		2011		2010
Net sales	$	702	$	691	$	662
Distribution fees and royalty expense		291		287		275
Research and development expense reimbursement to Lilly - necitumumab		14		12		12
Amortization (income)/expense – upfront, milestone and other licensing payments		38		37		37
Commercialization expense reimbursements to/(from) Lilly		(20)		(18)		(16)
Japan commercialization profit sharing (income)/expense, net		(37)		(34)		(39)
			December 31,
Dollars in Millions			2012		2011
Other intangible assets – upfront, milestone and other licensing payments			$	211	$	249

Gilead [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

	Year Ended December 31,
Dollars in Millions	2012		2011		2010
Net sales	$	1,267	$	1,204	$	1,053
Equity in net loss of affiliates		(18)		(16)		(12)

AstraZeneca [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Year Ended December 31,
Dollars in Millions		2012		2011		2010
Net sales		$	972	$	473	$	158
Profit sharing expense			425		207		67
Commercialization expense reimbursements to/(from) AstraZeneca			(141)		(40)		(33)
Research and development expense reimbursements to/(from) AstraZeneca			(18)		40		19
Amortization (income)/expense – upfront, milestone and other licensing payments recognized in:
	Cost of products sold		(126)		-		-
	Other (income)/expense		(38)		(38)		(28)
Upfront, milestone and other licensing payments received:
	Amylin-related products		3,547		-		-
	Saxagliptin		-		-		50
	Dapagliflozin		-		120		-
				December 31,
Dollars in Millions				2012		2011
Deferred income – upfront, milestone and other licensing payments:
	Amylin-related products			$	3,423	$	-
	Saxagliptin				208		230
	Dapagliflozin				206		142

Pfizer [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

	Year Ended December 31,
Dollars in Millions	2012		2011		2010
Net sales	$	2	$	-	$	-
Commercialization expense reimbursements to/(from) Pfizer		(18)		(10)		(8)
Research and development reimbursements to/(from) Pfizer		7		(65)		(190)
Amortization (income)/expense – upfront, milestone and other licensing payments		(37)		(33)		(31)
Upfront, milestone and other licensing payments received		20		65		10
			December 31,
Dollars in Millions			2012		2011
Deferred income – upfront, milestone and other licensing payments			$	397	$	434